No Data Yet
Gilead Sciences appointed 14-year company veteran Keeley Wettan as its new Executive Vice President and General Counsel on December 18, 2025.
Valuation analysis shows Gilead Sciences (GILD) is undervalued by 53.4% based on a discounted cash flow model, despite the stock gaining 37.6% over the past year.
Companies including Gilead Sciences, Applied Materials, and Qualcomm are leveraging substantial free cash flow—up to $5.7 billion annually—to fund significant shareholder returns through dividends and stock buybacks.
Gilead Sciences announced its investigational HIV treatment, a combination of bictegravir and lenacapavir (BIC/LEN), met its primary endpoint in a Phase 3 trial, demonstrating non-inferiority to its own market-leading drug, BIKTARVY, for maintaining viral suppression.
Gilead's Kite unit reported positive new analysis for its Yescarta cell therapy as a second-line lymphoma treatment, reinforcing its oncology franchise. The win provides a crucial boost as the company navigates a major setback in its lung cancer pipeline, highlighting the high-stakes nature of its diversification strategy.
Abbott Laboratories showcases a strong balance sheet with reduced debt and high interest coverage, presenting a stable profile amid a volatile healthcare sector focused on obesity drugs and policy shifts.
Merck announced an increased dividend to $0.85 per share, creating a 3.4% forward yield. The move signals confidence in its financial stability and commitment to shareholder returns, even as the company faces a new FDA safety review for its RSV antibody treatment, Enflonsia.
U.S. healthcare and pharmaceutical stocks are facing a period of heightened volatility driven by the obesity drug arms race, shifting U.S. policy on healthcare subsidies, and an increasingly dual-natured FDA that is both accelerating approvals and intensifying safety scrutinies. These factors create a complex investment landscape heading into the week of December 15, 2025.
Immunovant is now prioritizing its next-generation antibody, IMVT-1402, for Graves' Disease, following a successful $550M capital raise. This strategic pivot sharpens the company's clinical focus and solidifies its financial runway through potential commercialization.
Arcus Biosciences and partner Gilead Sciences are discontinuing a Phase III trial for their anti-TIGIT cancer therapy, domvanalimab, after it failed to improve patient survival. The news caused Arcus stock to plunge, erasing an eight-month rally, and prompted a strategic pivot.
Eli Lilly presented updated Phase 3 data for its breast cancer drug, imlunestrant, demonstrating a notable reduction in disease progression. The results reinforce the drug's potential in a competitive oncology landscape marked by both rapid innovation and high-profile clinical setbacks.
Recent warnings from Procter & Gamble's (PG) CFO about a "nervous" and slowing U.S. consumer have validated bearish calls on weaker consumer staples stocks. This pressure comes despite aggressive corporate strategies involving price hikes and significant restructuring.
Arcellx and partner Kite (Gilead) announced strong Phase 2 data for their multiple myeloma CAR-T therapy, anito-cel, showing high response rates and durable efficacy. The results, presented at the ASH Annual Meeting, intensify competition in the crowded cell therapy market.
Kymera Therapeutics reported positive Phase 1b results for its anti-inflammatory drug, KT-621, causing its stock to surge 46%. The data demonstrated a significant reduction in inflammatory biomarkers, boosting investor confidence in its potential for treating Type 2 inflammatory diseases.